Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to identify and manage the unique adverse events associated with immune checkpoint inhibition? Read this expert commentary to get up to speed.
Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to best use this agent in your clinical practice? Read this expert commentary to get up to speed.
Are you aware of the latest data on immune checkpoint inhibition for the treatment of early-stage TNBC? Read my thoughts on the promise of this strategy for our patients with this disease.
Are you aware of new strategies using combination immunotherapy in the treatment of metastatic TNBC? Read my thoughts on this promising approach to potentially improve response to immunotherapy in these patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.